154 results on '"Hier M"'
Search Results
2. A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-Associated Head and Neck Cancer With Implications for Treatment Deintensification and Immunotherapy
- Author
-
Zeng, P., primary, Cecchini, M., additional, Barrett, J., additional, Shammas-Toma, M., additional, De Cecco, L., additional, Serafini, M., additional, Cavalieri, S., additional, Licitra, L., additional, Hoebers, F., additional, Brakenhoff, R., additional, Leemans, C., additional, Scheckenbach, K., additional, Poli, T., additional, Wang, X., additional, Liu, X., additional, Laxague, F., additional, Prisman, E., additional, Poh, C., additional, Bose, P., additional, Dort, J., additional, Shaikh, M., additional, Ryan, S., additional, Dawson, A., additional, Khan, M., additional, Howlett, C., additional, Stecho, W., additional, Plantinga, P., additional, da Silva, S., additional, Hier, M., additional, Khan, H., additional, MacNeil, D., additional, Mendez, A., additional, Yoo, J., additional, Fung, K., additional, Lang, P., additional, Winquist, E., additional, Palma, D., additional, Ziai, H., additional, Li, S., additional, Boutros, P., additional, Mymryk, J., additional, and Nichols, A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. A Randomized Trial of Radiotherapy vs. Trans-Oral Surgery for Treatment De-Escalation in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (ORATOR2)
- Author
-
Palma, D.A., primary, Prisman, E., additional, Berthelet, E., additional, Tran, E., additional, Hamilton, S.N., additional, Wu, J., additional, Eskander, A., additional, Higgins, K., additional, Karam, I., additional, Poon, I., additional, Husain, Z.A., additional, Enepekides, D., additional, Hier, M., additional, Sultanem, K., additional, Richardson, K., additional, Mlynarek, A., additional, Johnson-Obaseki, S., additional, Eapen, L., additional, Odell, M., additional, Bayley, A.J., additional, Dowthwaite, S., additional, Jackson, J.E., additional, Dzienis, M., additional, O'Neil, J., additional, Chandarana, S., additional, Banerjee, R.N., additional, Hart, R., additional, Chung, J., additional, Tenenholz, T.C., additional, Krishnan, S., additional, Le, H.V., additional, Yoo, J., additional, Mendez, A., additional, Winquist, E., additional, Kuruvilla, S., additional, Stewart, P., additional, Warner, A., additional, Mitchell, S., additional, Chen, J., additional, Parker, C., additional, Wehrli, B., additional, Kwan, K., additional, Theurer, J., additional, Sathya, J., additional, Hammond, J.A., additional, Read, N.E., additional, Venkatesan, V.M., additional, MacNeil, D., additional, Fung, K., additional, and Nichols, A., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Head and neck cancer:emerging concepts in biomarker discovery and opportunities for clinical translation
- Author
-
Kowalski, L. P. (Luiz Paulo), Coletta, R. D. (Ricardo Della), Salo, T. (Tuula), Maschietto, M. (Mariana), Chojniak, R. (Rubens), Lima, J. M. (Jefferson Muniz), Mlynarek, A. (Alex), Hier, M. P. (Michael P.), Alaoui‐Jamali, M. A. (Moulay A.), and Silva, S. D. (Sabrina Daniela)
- Published
- 2020
5. Teaching head and neck cancer patients coping strategies: results of a feasibility study
- Author
-
Allison, P.J, Nicolau, B, Edgar, L, Archer, J, Black, M, and Hier, M
- Published
- 2004
- Full Text
- View/download PDF
6. Clinicopathological relevance of antithyroglobulin antibodies in low-risk papillary thyroid cancer
- Author
-
Morand, G B, da Silva, S D, Mlynarek, A M, Black, M J, Payne, R J, Hier, M P, University of Zurich, and Hier, M P
- Subjects
2733 Otorhinolaryngology ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology - Published
- 2017
7. The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017
- Author
-
Kuenstner, JT, Naser, S, Chamberlin, W, Borody, T, Graham, DY, McNees, A, Hermon-Taylor, J, Hermon-Taylor, A, Dow, CT, Thayer, W, Biesecker, J, Collins, MT, Sechi, LA, Singh, SV, Zhang, P, Shafran, I, Weg, S, Telega, G, Rothstein, R, Oken, H, Schimpff, S, Bach, H, Bull, T, Grant, I, Ellingson, J, Dahmen, H, Lipton, J, Gupta, S, Chaubey, K, Singh, M, Agarwal, P, Kumar, A, Misri, J, Sohal, J, Dhama, K, Hemati, Z, Davis, W, Hier, M, Aitken, J, Pierce, E, Parrish, N, Goldberg, N, Kali, M, Bendre, S, Agrawal, G, Baldassano, R, Linn, P, Sweeney, RW, Fecteau, M, Hofstaedter, C, Potula, R, Timofeeva, O, Geier, S, John, K, Zayanni, N, Malaty, HM, Kahlenborn, C, Kravitz, A, Bulfon, A, Daskalopoulos, G, Mitchell, H, Neilan, B, Timms, V, Cossu, D, Mameli, G, Angermeier, P, Jelic, T, Goethe, R, Juste, RA, and Kuenstner, L
- Abstract
On March 24 and 25, 2017 researchers and clinicians from around the world met at Temple University in Philadelphia to discuss the current knowledge of Mycobacterium avium ssp. paratuberculosis (MAP) and its relationship to human disease. The conference was held because of shared concern that MAP is a zoonotic bacterium that poses a threat not only to animal health but also human health. In order to further study this problem, the conferees discussed ways to improve MAP diagnostic tests and discussed potential future anti-MAP clinical trials. The conference proceedings may be viewed on the www.Humanpara.org website. A summary of the salient work in this field is followed by recommendations from a majority of the conferees.
- Published
- 2017
8. Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy
- Author
-
Roskies, M., primary, Kay-Rivest, E., additional, Mascarella, M. A., additional, Sultanem, K., additional, Mlynarek, A., additional, and Hier, M., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Survival and quality of life in oropharyngeal cancer patients treated with primary chemoradiation after salivary gland transfer
- Author
-
Morand, G B, primary, Madana, J, additional, Da Silva, S D, additional, Roskies, M, additional, Sultanem, K, additional, Black, M J, additional, Mlynarek, A M, additional, and Hier, M P, additional
- Published
- 2016
- Full Text
- View/download PDF
10. Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer?
- Author
-
Hosseini, S., primary, Payne, R. J., additional, Zawawi, F., additional, Mlynarek, A., additional, Hier, M. P., additional, Tamilia, M., additional, and Forest, V. I., additional
- Published
- 2016
- Full Text
- View/download PDF
11. Merkel cell carcinoma of the head and neck: poorer prognosis than non-head and neck sites
- Author
-
Morand, G B, primary, Madana, J, additional, Da Silva, S D, additional, Hier, M P, additional, Mlynarek, A M, additional, and Black, M J, additional
- Published
- 2016
- Full Text
- View/download PDF
12. Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients
- Author
-
Varshney, R, primary, Pakdaman, M N, additional, Sands, N, additional, Hier, M P, additional, Rochon, L, additional, Black, M J, additional, and Payne, R J, additional
- Published
- 2014
- Full Text
- View/download PDF
13. The Impact of FDG-PET Imaging on the Clinical Management and Radiation Therapy Planning in Patients With Head-and-Neck Squamous Cell Carcinoma
- Author
-
Waters, A., primary, Sultanem, K., additional, Bahoric, B., additional, Hier, M., additional, and Deblois, F., additional
- Published
- 2012
- Full Text
- View/download PDF
14. Extra-Cranial head and neck schwannomas: The McGill experience
- Author
-
Al-Qahtani, K, primary, Anand, S, additional, Black, M, additional, Hier, M, additional, Kost, K, additional, and Zeitouni, A, additional
- Published
- 2012
- Full Text
- View/download PDF
15. Organ Preservation using HDR Brachytherapy for Locally Advanced Head and Neck Cancers: A Single Center Experience
- Author
-
Duclos, M., primary, Al-Hamad, A., additional, Al-Halabi, H., additional, Alsuhaibani, A., additional, Kost, K., additional, Zeitouni, A., additional, Hier, M., additional, Shenouda, G., additional, and Black, M., additional
- Published
- 2009
- Full Text
- View/download PDF
16. Does HDR Brachytherapy for Primary or Recurrent Head and Neck Cancers have Lower Local Control than the External Beam Radiotherapy?
- Author
-
Al Hamad, A.N., primary, Black, M., additional, Shenouda, G., additional, Zeitouni, A., additional, Kost, K., additional, Hier, M., additional, Bahoric, B., additional, and Duclos, M., additional
- Published
- 2008
- Full Text
- View/download PDF
17. A concerted cell and serum proteomic approach for the identification of oral squamous cell carcinoma biomarkers
- Author
-
Mlynarek, A. M., primary, Balys, R., additional, Jie, S., additional, Xu, Y., additional, Hier, M. P., additional, Black, M. J., additional, and Alaoui-Jamali, M. A., additional
- Published
- 2006
- Full Text
- View/download PDF
18. 183 Differential dose allocation to variable sub-volumes of head and neck (H/N) squamous cell carcinoma (SCCa), using intensity-modulated radiotherapy (IMRT): A phase II dose escalation study
- Author
-
Niazi, T-M., primary, Sultanern, K., additional, Shenouda, G., additional, Hier, M., additional, Corns, R., additional, Lavole, I., additional, Skelly, J., additional, and Black, M., additional
- Published
- 2005
- Full Text
- View/download PDF
19. Results of a feasibility study for a psycho-educational intervention in head and neck cancer
- Author
-
Allison, P.J., primary, Edgar, L., additional, Nicolau, B., additional, Archer, J., additional, Black, M., additional, and Hier, M., additional
- Published
- 2004
- Full Text
- View/download PDF
20. 45 Organ-preservation treatment in locally advanced (stage III and IV) base of tongue and oral tongue carcinoma
- Author
-
Duclos, M., primary, Black, M., additional, Hier, M., additional, Zeitouni, A., additional, Kost, K., additional, Sedaghi, N., additional, Vuongl, T., additional, Shenouda, G., additional, Sultaneml, K., additional, and Dionisopoulos, T., additional
- Published
- 2001
- Full Text
- View/download PDF
21. Generation of Therapeutic T Cells From Draining Lymph Nodes in a Murine Model of Head and Neck Squamous Cell Carcinoma
- Author
-
Sadeghi, N., primary, Black, M. J., additional, Hier, M. P., additional, Shenouda, G., additional, and Karp, S. E., additional
- Published
- 1997
- Full Text
- View/download PDF
22. Sentinel lymph node biopsy in thyroid cancer: it can work but there are pitfalls.
- Author
-
Amir A, Payne R, Richardson K, Hier M, Mlynarek A, and Caglar D
- Published
- 2011
23. Resident's page: pathology.
- Author
-
Yoskovitch A, Hier M, Begin LR, Black M, Bikhazi NB, Eriksson TP, and Singer MI
- Published
- 1998
24. Overexpression of tumor necrosis receptor-associated factor (TRAF) family in tongue squamous cell carcinoma is associated with poor diferentiation status and progression to metastasis
- Author
-
Silvia Rogatto, Sabrina Daniela da Silva, Xu, B., Alkailani, M. I., Krikor Bijian, Alex Mlynarek, Hier, M., Alaoui-Jamali, Moulay A., and Lp, Kowalski
25. Can calcium antagonists affect the hemostatic mechanism and promote rebleeding? An experimental study
- Author
-
Arbit, E, primary, Kaplan, R, additional, Gillich, A, additional, Brem, S, additional, and Hier, M, additional
- Published
- 1987
- Full Text
- View/download PDF
26. S025 Biomarkers of Invasiveness in Oral Squamous Cell Carcinoma: A Cell Proteomic Approach
- Author
-
Mlynarek, A. M., Balys, R. L., Hier, M. P., Black, M. J., and Alaoui-Jamali, M. A.
- Published
- 2006
- Full Text
- View/download PDF
27. Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial.
- Author
-
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Johnson-Obaseki S, Odell M, Corsten M, Parker C, Wehrli B, Kwan K, and Palma DA
- Abstract
Radiotherapy (RT) and transoral robotic surgery (TORS) are both curative-intent treatment options for oropharyngeal squamous cell carcinoma (OPSCC). Herein, we report the final outcomes of the ORATOR trial comparing these modalities, 5 years after enrollment completion. We randomly assigned 68 patients with T1-2N0-2 OPSCC to RT (with chemotherapy if node-positive) versus TORS plus neck dissection (± adjuvant RT/chemoradiation). The primary end point was swallowing quality of life (QOL) assessed with the MD Anderson Dysphagia Inventory (MDADI). Secondary end points included overall and progression-free survival (OS, PFS), adverse events (AEs), and other QOL metrics. The primary end point has been previously reported (Nichols 2019). In this report, the median follow-up was 5.1 years (IQR, 5.0-5.3 years). MDADI total scores converged by 5 years and were not significantly different across the follow-up period ( P = .11). EORTC QLQ-C30 and H&N35 scores demonstrated differing profiles, including worse dry mouth in the RT arm ( P = .032) and worse pain in the TORS arm ( P = .002). Grade 2-5 AE rates did not differ between arms (91% [n = 31] v 97% [n = 33] respectively, P = .61), with more neutropenia and hearing loss in the RT arm, and more dysphagia and other pain in the TORS arm based on grades 2-5 (all P < .05). There were no differences in OS or PFS. In conclusion, toxicity and QOL profiles differ in some domains between RT and TORS, but oncologic outcomes were excellent in both arms. Choice of treatment should remain a shared decision between the patient and their providers.
- Published
- 2024
- Full Text
- View/download PDF
28. Predicting short-term treatment toxicity in head and neck cancer through a systematic review and meta-analysis.
- Author
-
Mascarella MA, Vendra V, Sultanem K, Tsien C, Shenouda G, Sridharan S, Bouganim N, Esfahani K, Richardson K, Mlynarek A, Hier M, Sadeghi N, Duvvuri U, and Kergoat MJ
- Abstract
Introduction: Frailty is a recognized condition associated with poorer outcomes in patients with head and neck cancer (HNC). The objective of this study was to ascertain the prognostic significance of various frailty metrics on short-term treatment toxicity in patients with HNC undergoing curative-intent therapy., Materials and Methods: A systematic review was performed searching multiple databases. An inverse-variation, random-effects model was used to perform the meta-analysis to evaluate the prognostic significance of various frailty metrics on short-term treatment-related toxicity in this population., Results: A total of 292,560 patients with HNC originating from 36 observational studies were analyzed. The most frequently reported frailty metrics were the modified frailty index (mFI), Geriatric 8 questionnaire (G8), Adjusted Clinical Groups (ACG), Groningen Frailty Indicator (GFI), and comprehensive geriatric assessment (CGA). The overall prevalence of frailty using any metric in all included studies was 7.5 %. The combined odds ratio (OR) for short-term treatment toxicity using the mFI was 2.60 (95 % CI of 1.81-3.72), G8 2.69 (95 % CI 1.37-5.28), ACG 3.43 (95 %CI 2.52-4.67), GFI 2.71 (95 % CI 1.11-6.62), and CGA 3.36 (95 % CI 1.18-9.53). The association of frailty with short-term treatment toxicity using various frailty metrics was more pronounced in patients with upfront surgery (OR 3.00, 95 %CI of 2.35-3.81) compared to definitive (chemo)radiotherapy 2.64 (95 % CI 1.04-6.68)., Discussion: Various frailty metrics exists in the HNC literature, with the most common being the mFI, G8, ACG, GFI, and CGA. Patients with HNC and frailty are more than twice as likely to suffer a short-term treatment-related toxicity when undergoing curative-intent HNC treatment than patients without frailty. This effect is more pronounced in patients undergoing upfront surgery., Competing Interests: Declaration of Competing Interest None of the authors have conflicts of interest to disclose., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
29. Genetic Risk For Depression and Quality of Life in Patients With Head and Neck Cancer.
- Author
-
Henry M, Chen LM, Ducharme L, Devault-Tousignant C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Richardson K, Chartier G, Mascarella M, Sadeghi N, Sultanem K, Shenouda G, Cury FL, and Meaney M
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Aged, Adult, Genetic Predisposition to Disease, Longitudinal Studies, Risk Factors, Surveys and Questionnaires, Quality of Life, Head and Neck Neoplasms psychology, Head and Neck Neoplasms genetics, Head and Neck Neoplasms therapy, Depression
- Abstract
Importance: Although patients with head and neck cancer (HNC) have been shown to experience high distress, few longitudinal studies include a comprehensive evaluation of biopsychosocial factors affecting quality of life (QoL), including genetic risk for depression., Objective: To identify factors at the time of cancer diagnosis associated with QoL scores at 3 months after treatment in patients newly diagnosed with a first occurrence of HNC., Design, Setting, and Participants: This prospective longitudinal study of 1464 participants with a 3-month follow-up, including structured clinical interviews and self-administered measures was carried out at the Department of Otolaryngology Head and Neck Surgery at 2 tertiary care McGill University Affiliated Hospitals, McGill University Health Centre, and Jewish General Hospital. Eligible patients were adults newly diagnosed within 2 weeks with a primary first occurrence of HNC, had a Karnofsky Performance Scale score higher than 60, and an expected survival of more than 6 months. Two hundred and twenty-three patients (72%) consented to participate and completed the baseline questionnaire, and 71% completed the 3-month follow-up measures., Exposures: An a priori conceptual model including sociodemographics, medical variables, psychosocial risk factors, and a polygenic risk score for depression (PRS-D) was tested., Main Outcomes and Measures: The Functional Assessment of Cancer Therapy-Head and Neck measured QoL at baseline and at 3 months., Results: Participants were mostly men (68.7%), with a mean (range) age of 62.9 (31-92) years, 36.6% having a university degree, 35.6% living alone, and 71.4% diagnosed with advanced HNC with mostly cancers being of the oropharynx (42.2%), oral cavity (17%), and larynx (16.3%). QoL at 3 months after HNC diagnosis was associated with higher PRS-D (B = -4.71; 95% CI, -9.18 to -0.23), and a diagnosis of major depressive disorder within 2 weeks of an HNC diagnosis (B = -32.24; 95% CI, -51.47 to 13.02), lifetime suicidal ideation (B = -22.39; 95% CI, -36.14 to -8.65), living with someone (B = 12.48; 95% CI, 3.43-21.52), having smoked cigarettes in the past 30 days pre-HNC diagnosis (B = -15.50; 95% CI, -26.07 to -4.93), chemotherapy type (B = -11.13; 95% CI, -21.23 to -1.02), and total radiotherapy dose (Gy) (B = -0.008; 95% CI, -0.01 to -0.002)., Conclusions and Relevance: This study identified the predictive value of a genetic predisposition to depression on QoL and function immediately after oncologic treatments. These findings highlight the potential importance of genetic profiling pretreatment to identify those most susceptible to experience QoL and functional compromise. Depression is a clear area of public health concern and should be a central focus in the treatment of patients with HNC.
- Published
- 2024
- Full Text
- View/download PDF
30. Sarcopenia predicts short-term treatment-related toxicity in patients undergoing curative-intent therapy for head and neck cancer: A systematic review and meta-analysis.
- Author
-
Mascarella MA, Ferdus J, Vendra V, Sridharan S, Sultanem K, Tsien C, Shenouda G, Bouganim N, Esfahani K, Richardson K, Mlynarek A, Sadeghi N, Hier M, and Kergoat MJ
- Subjects
- Humans, Male, Female, Sarcopenia etiology, Sarcopenia therapy, Head and Neck Neoplasms therapy
- Abstract
Sarcopenia is an increasingly recognized biomarker associated with poorer outcomes. The objective of this study was to ascertain the effect of sarcopenia on treatment tolerance and short-term toxicity in head and neck cancer (HNC). A systematic review was performed using multiple databases. An inverse-variation, random-effects model was used to perform the meta-analysis to evaluate the effect of sarcopenia on severe treatment toxicity and poor treatment tolerance. Sixteen observational studies, including 3187 patients with HNC, were analyzed. The combined odds ratio (OR) for severe treatment toxicity and tolerance was 2.22 (95%CI 1.50-3.29) and 1.40 (95%CI 0.84-2.32), respectively. The effect of sarcopenia on short-term severe treatment toxicity was similar with upfront surgery (OR 2.03, 95%CI 1.22-3.37) and definitive radiotherapy (OR 2.24, 95%CI 1.18-4.27) Patients with sarcopenia are more than twice as likely to suffer a short-term treatment-related toxicity when undergoing curative-intent HNC treatment., (© 2024 The Authors. Head & Neck published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
31. Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer.
- Author
-
Muniz IAF, Araujo M, Bouassaly J, Farshadi F, Atique M, Esfahani K, Bonan PRF, Hier M, Mascarella M, Mlynarek A, Alaoui-Jamali M, and Silva SDD
- Subjects
- Humans, Cetuximab therapeutic use, Docetaxel, Nivolumab, Papillomavirus Infections complications, Papillomavirus Infections drug therapy, Oropharyngeal Neoplasms etiology, Oropharyngeal Neoplasms therapy
- Abstract
The use of conventional chemotherapy in conjunction with targeted and immunotherapy drugs has emerged as an option to limit the severity of side effects in patients diagnosed with head and neck cancer (HNC), particularly oropharyngeal cancer (OPC). OPC prevalence has increased exponentially in the past 30 years due to the prevalence of human papillomavirus (HPV) infection. This study reports a comprehensive review of clinical trials registered in public databases and reported in the literature (PubMed/Medline, Scopus, and ISI web of science databases). Of the 55 clinical trials identified, the majority (83.3%) were conducted after 2015, of which 77.7% were performed in the United States alone. Eight drugs have been approved by the FDA for HNC, including both generic and commercial forms: bleomycin sulfate, cetuximab (Erbitux), docetaxel (Taxotere), hydroxyurea (Hydrea), pembrolizumab (Keytruda), loqtorzi (Toripalimab-tpzi), methotrexate sodium (Trexall), and nivolumab (Opdivo). The most common drugs to treat HPV-associated OPC under these clinical trials and implemented as well for HPV-negative HNC include cisplatin, nivolumab, cetuximab, paclitaxel, pembrolizumab, 5-fluorouracil, and docetaxel. Few studies have highlighted the necessity for new drugs specifically tailored to patients with HPV-associated OPC, where molecular mechanisms and clinical prognosis are distinct from HPV-negative tumors. In this context, we identified most mutated genes found in HPV-associated OPC that can represent potential targets for drug development. These include TP53 , PIK3CA , PTEN , NOTCH1 , RB1 , FAT1 , FBXW7 , HRAS , KRAS, and CDKN2A .
- Published
- 2024
- Full Text
- View/download PDF
32. Rethinking treatment paradigms: Neoadjuvant therapy and de-escalation strategies in HPV-positive head and neck cancer.
- Author
-
Bouassaly J, Karimi N, Kowalski LP, Sultanem K, Alaoui-Jamali M, Mlynarek A, Mascarella M, Hier M, Sadeghi N, and da Silva SD
- Subjects
- Humans, Neoadjuvant Therapy, Chemoradiotherapy, Oropharyngeal Neoplasms therapy, Papillomavirus Infections complications, Head and Neck Neoplasms therapy, Head and Neck Neoplasms complications
- Abstract
Head and neck cancer (HNC) is the 6th most common cancer across the world, with a particular increase in HNC associated with human papilloma virus (HPV) among younger populations. Historically, the standard treatment for this disease consisted of combined surgery and radiotherapy or curative platinum-based concurrent chemoradiotherapy, with associated long term and late toxicities. However, HPV-positive HNC is recognized as a unique cancer subtype, typically with improved clinical outcomes. As such, treatment de-escalation strategies have been widely researched to mitigate the adverse effects associated with the current standard of care without compromising efficacy. These strategies include treatment de-escalation, such as novel surgical techniques, alternative radiation technologies, radiation dose and volume reduction, as well as neoadjuvant chemotherapies, immunotherapies, and combined therapies. Although these therapies show great promise, many of them are still under investigation due to hesitation surrounding their widespread implementation. The objective of this review is to summarize the most recent progress in de-escalation strategies and neoadjuvant therapies designed for HPV-positive HNC. While specific treatments may require additional research before being widely adopted, encouraging results from recent studies have highlighted the advantages of neoadjuvant chemotherapy and immunotherapy, as well as radiation and surgical de-escalation approaches in managing HPV-positive HNC., Competing Interests: Declaration of Competing Interest The authors declare no competing interests., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma.
- Author
-
Atique M, Muniz I, Farshadi F, Hier M, Mlynarek A, Macarella M, Maschietto M, Nicolau B, Alaoui-Jamali MA, and da Silva SD
- Abstract
(1) Background: Head and neck cancer (HNC) ranks as the sixth most prevalent cancer in the world. In addition to the traditional risk factors such as alcohol and tobacco consumption, the implication of the human papillomavirus (HPV) is becoming increasingly significant, particularly in oropharyngeal cancer (OPC). (2) Methods: This study is based on a review analysis of different articles and repositories investigating the mutation profile of HPV-related OPC and its impact on patient outcomes. (3) Results: By compiling data from 38 datasets involving 8311 patients from 12 countries, we identified 330 genes that were further analyzed. These genes were enriched for regulation of the inflammatory response ( RB1 , JAK2 , FANCA , CYLD , SYK , ABCC1 , SYK , BCL6 , CEBPA , SRC , BAP1 , FOXP1 , FGR , BCR , LRRK2 , RICTOR , IGF1 , and ATM ), among other biological processes. Hierarchical cluster analysis showed the most relevant biological processes were linked with the regulation of mast cell cytokine production, neutrophil activation and degranulation, and leukocyte activation (FDR < 0.001; p -value < 0.05), suggesting that neutrophils may be involved in the development and progression of HPV-related OPC. (4) Conclusions: The neutrophil infiltration and HPV status emerge as a potential prognostic factor for OPC. HPV-infected HNC cells could potentially lead to a decrease in neutrophil infiltration. By gaining a better molecular understanding of HPV-mediated neutrophil immunosuppression activity, it is possible to identify a meaningful target to boost antitumor immune response in HNC and hence to improve the survival of patients with HNC.
- Published
- 2023
- Full Text
- View/download PDF
34. Oncologic Significance of Therapeutic Delays in Patients With Oral Cavity Cancer.
- Author
-
Dayan GS, Bahig H, Johnson-Obaseki S, Eskander A, Hong X, Chandarana S, de Almeida JR, Nichols AC, Hier M, Belzile M, Gaudet M, Dort J, Matthews TW, Hart R, Goldstein DP, Yao CMKL, Hosni A, MacNeil D, Fowler J, Higgins K, Khalil C, Khoury M, Mlynarek AM, Morand G, Sultanem K, Maniakas A, Ayad T, and Christopoulos A
- Subjects
- Male, Humans, Female, Cohort Studies, Canada, Time-to-Treatment, Mouth Neoplasms therapy, Mouth Neoplasms mortality
- Abstract
Importance: Oral cavity cancer often requires multidisciplinary management, subjecting patients to complex therapeutic trajectories. Prolonged treatment intervals in oral cavity cancer have been associated with poor oncological outcomes, but there has yet to be a study investigating treatment times in Canada., Objective: To report treatment delays for patients with oral cavity cancer in Canada and evaluate the outcomes of treatment delays on overall survival., Design, Setting, and Participants: This multicenter cohort study was performed at 8 Canadian academic centers from 2005 to 2019. Participants were patients with oral cavity cancer who underwent surgery and adjuvant radiation therapy. Analysis was performed in January 2023., Main Outcomes and Measures: Treatment intervals evaluated were surgery to initiation of postoperative radiation therapy interval (S-PORT) and radiation therapy interval (RTI). The exposure variables were prolonged intervals, respectively defined as index S-PORT greater than 42 days and RTI greater than 46 days. Patient demographics, Charlson Comorbidity Index, smoking status, alcohol status, and cancer staging were also considered. Univariate (log rank and Kaplan-Meier) and multivariate (Cox regression) analyses were performed to determine associations with overall survival (OS)., Results: Overall, 1368 patients were included; median (IQR) age at diagnosis was 61 (54-70) years, and 896 (65%) were men. Median (IQR) S-PORT was 56 (46-68) days, with 1093 (80%) patients waiting greater than 42 days, and median (IQR) RTI was 43 (41-47) days, with 353 (26%) patients having treatment time interval greater than 46 days. There were variations in treatment time intervals between institutions for S-PORT (institution with longest vs shortest median S-PORT, 64 days vs 48 days; η2 = 0.023) and RTI (institution with longest vs shortest median RTI, 44 days vs 40 days; η2 = 0.022). Median follow-up was 34 months. The 3-year OS was 68%. In univariate analysis, patients with prolonged S-PORT had worse survival at 3 years (66% vs 77%; odds ratio 1.75; 95% CI, 1.27-2.42), whereas prolonged RTI (67% vs 69%; odds ratio 1.06; 95% CI, 0.81-1.38) was not associated with OS. Other factors associated with OS were age, Charlson Comorbidity Index, alcohol status, T category, N category, and institution. In the multivariate model, prolonged S-PORT remained independently associated with OS (hazard ratio, 1.39; 95% CI, 1.07-1.80)., Conclusions and Relevance: In this multicenter cohort study of patients with oral cavity cancer requiring multimodal therapy, initiation of radiation therapy within 42 days from surgery was associated with improved survival. However, in Canada, only a minority completed S-PORT within the recommended time, whereas most had an appropriate RTI. An interinstitution variation existed in terms of treatment time intervals. Institutions should aim to identify reasons for delays in their respective centers, and efforts and resources should be directed toward achieving timely completion of S-PORT.
- Published
- 2023
- Full Text
- View/download PDF
35. Genetic predisposition to depression and inflammation impacts symptom burden and survival in patients with head and neck cancer: A longitudinal study.
- Author
-
Henry M, Harvey R, Chen LM, Meaney M, Nguyen TTT, Kao HT, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Richardson K, Greenwood CMT, Melnychuk D, Gold P, Chartier G, Black M, Mascarella M, MacDonald C, Sadeghi N, Sultanem K, Shenouda G, Cury F, and O'Donnell KJ
- Subjects
- Adult, Humans, Longitudinal Studies, Prospective Studies, Depression genetics, Depression diagnosis, Anxiety genetics, Anxiety psychology, Inflammation genetics, Genetic Predisposition to Disease genetics, Head and Neck Neoplasms genetics
- Abstract
Objective: The primary purpose of this study was to investigate the contribution of genetic predispositions to depression and inflammation, as measured through polygenic risk scores, on symptom burden (physical and psychological) in patients with head and neck cancer in the immediate post-treatment period (i.e., at three months post-diagnosis), as well as on 3-, 6-, 12-, 24- and 36-month survival., Methods: Prospective longitudinal study of 223 adults (72 % participation) newly diagnosed with a first occurrence of primary head and neck cancer, paired with genetic data (Illumina PsychArray), validated psychometric measures, Structured Clinical Interviews for DSM Disorders (SCID-I), and medical chart reviews., Results: Symptom burden at 3 months was predicted by (R
2 adj. = 0.38, p < 0.001): a baseline SCID-I Anxiety Disorder (b = 1.69, B = 0.23, 95%CI = 0.43-2.94; p = 0.009), baseline levels of HADS anxiety (b = 0.20, B = 0.29, 95%CI = 0.07-0.34; p = 0.003), the polygenic risk score (PRS) for depression (b = 0.66, B = 0.18, 95%CI = 0.003-1.32; p = 0.049), and cumulated dose of radiotherapy (b = 0.002, B = 0.46, 95%CI = 0.001-0.003; p < 0.001). When controlling for factors known to be associated with cancer survival, patients with a higher PRS associated with depression and inflammation, respectively, presented higher risk of death within 36 months (b = 1.75, Exp(B) = 5.75, 95%CI = 1.55-21.27, p = 0.009 and b = 0.14, Exp(B) = 1.15, 95%CI = 1.01-1.30, p = 0.03)., Conclusions: Our results outline three potential pathways of symptom burden in patients with head and neck cancer: a genetic predisposition towards depression; an initial anxiety disorder upon being diagnosed with cancer or high levels of anxiety upon diagnosis; and a dose-related response to radiotherapy. One may want to investigate early interventions in these areas to alleviate symptom burden in patients faced with a life-threatening disease, as well as consider targeting genetic predisposition towards depression and inflammation implicated in survival. The high prevalence of distress in patients with head and neck cancer is an opportunity to study genetic predispositions, which could potentially be broadly generalized to other cancers and diseases., Competing Interests: Declaration of competing interest There is no conflict of interest related to this publication., (Published by Elsevier B.V.)- Published
- 2023
- Full Text
- View/download PDF
36. Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV 600E -Positive Papillary Thyroid Cancer.
- Author
-
da Silva SD, Morand GB, Diesel L, de Lima JM, Bijian K, Kailasam S, Lefebvre F, Bourque G, Hier M, and Alaoui-Jamali MA
- Subjects
- Humans, Thyroid Cancer, Papillary genetics, Thyroid Cancer, Papillary pathology, Mutation genetics, Neoplasm Recurrence, Local, Proto-Oncogene Proteins B-raf genetics, Thyroid Neoplasms metabolism, Carcinoma, Papillary genetics, Carcinoma, Papillary pathology
- Abstract
Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland and early stages are curable. However, a subset of PTCs shows an unusually aggressive phenotype with extensive lymph node metastasis and higher incidence of locoregional recurrence. In this study, we investigated a large cohort of PTC cases with an unusual aggressive phenotype using a high-throughput RNA sequencing (RNA-Seq) to identify differentially regulated genes associated with metastatic PTC. All metastatic PTC with mutated BRAF (V600E) but not BRAF wild-type expressed an up-regulation of R-Spondin Protein 4 (RSPO4) concomitant with an upregulation of genes involved in focal adhesion and cell-extracellular matrix signaling. Further immunohistochemistry validation confirmed the upregulation of these target genes in metastatic PTC cases. Preclinical studies using established PTC cell lines support that RSPO4 overexpression is associated with BRAF V600E mutation and is a critical upstream event that promote activation of kinases of focal adhesion signaling known to drive cancer cell locomotion and invasion. This finding opens up the potential of co-targeting B-Raf, RSPO and focal adhesion proteins as a pharmacological approach for aggressive BRAF V600E PTC.
- Published
- 2022
- Full Text
- View/download PDF
37. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.
- Author
-
Zeng PYF, Cecchini MJ, Barrett JW, Shammas-Toma M, De Cecco L, Serafini MS, Cavalieri S, Licitra L, Hoebers F, Brakenhoff RH, Leemans CR, Scheckenbach K, Poli T, Wang X, Liu X, Laxague F, Prisman E, Poh C, Bose P, Dort JC, Shaikh MH, Ryan SEB, Dawson A, Khan MI, Howlett CJ, Stecho W, Plantinga P, Daniela da Silva S, Hier M, Khan H, MacNeil D, Mendez A, Yoo J, Fung K, Lang P, Winquist E, Palma DA, Ziai H, Amelio AL, Li SS, Boutros PC, Mymryk JS, and Nichols AC
- Subjects
- Humans, Retrospective Studies, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Prognosis, Biomarkers, Human Papillomavirus Viruses, Papillomaviridae, Papillomavirus Infections complications, Oropharyngeal Neoplasms therapy, Head and Neck Neoplasms
- Abstract
Background: There is significant interest in treatment de-escalation for human papillomavirus-associated (HPV
+ ) oropharyngeal squamous cell carcinoma (OPSCC) patients given the generally favourable prognosis. However, 15-30% of patients recur after primary treatment, reflecting a need for improved risk-stratification tools. We sought to develop a molecular test to risk stratify HPV+ OPSCC patients., Methods: We created an immune score (UWO3) associated with survival outcomes in six independent cohorts comprising 906 patients, including blinded retrospective and prospective external validations. Two aggressive radiation de-escalation cohorts were used to assess the ability of UWO3 to identify patients who recur. Multivariate Cox models were used to assess the associations between the UWO3 immune class and outcomes., Findings: A three-gene immune score classified patients into three immune classes (immune rich, mixed, or immune desert) and was strongly associated with disease-free survival in six datasets, including large retrospective and prospective datasets. Pooled analysis demonstrated that the immune rich group had superior disease-free survival compared to the immune desert (HR = 9.0, 95% CI: 3.2-25.5, P = 3.6 × 10-5 ) and mixed (HR = 6.4, 95% CI: 2.2-18.7, P = 0.006) groups after adjusting for age, sex, smoking status, and AJCC8 clinical stage. Finally, UWO3 was able to identify patients from two small treatment de-escalation cohorts who remain disease-free after aggressive de-escalation to 30 Gy radiation., Interpretation: With additional prospective validation, the UWO3 score could enable biomarker-driven clinical decision-making for patients with HPV+ OPSCC based on robust outcome prediction across six independent cohorts. Prospective de-escalation and intensification clinical trials are currently being planned., Funding: CIHR, European Union, and the NIH., Competing Interests: Declaration of interests PYFZ, JWB, PCB, JSM and ACN have a US patent pending for the UWO3 score. All other authors declare no conflict of interest., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
38. Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma.
- Author
-
Castellano LRC, Cruz SBSC, Hier M, Bonan PRF, Alaoui-Jamali MA, and da Silva SD
- Abstract
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of malignancies which have shown exponential incidence in the last two decades especially due to human papillomavirus (HPV) infection. The HPV family comprises more than 100 types of viruses with HPV16 and HPV18 being the most prevalent strains in HNSCC. Literature data reveal that the mutation profile as well as the response to chemotherapy and radiotherapy are distinct among HPV+ versus HPV-negative tumors. Furthermore, the presence of the virus induces activation of an immune response, in particular the recruitment of specific antiviral T lymphocytes to tumor sites. These T cells when activated produce soluble factors including cytokines and chemokines capable of modifying the local immune tumor microenvironment and impact on tumor response to the treatment. In this comprehensive review we investigated current knowledge on how the presence of an HPV can modify the inflammatory response systemically and within the tumor microenvironment's immunological responses, thereby impacting on disease prognosis and survival. We highlighted the research gaps and emerging approaches necessary to discover novel immunotherapeutic targets for HPV-associated HNSCC.
- Published
- 2022
- Full Text
- View/download PDF
39. Above and Beyond Age: Prediction of Major Postoperative Adverse Events in Head and Neck Surgery.
- Author
-
Mascarella MA, Muthukrishnan N, Maleki F, Kergoat MJ, Richardson K, Mlynarek A, Forest VI, Reinhold C, Martin DR, Hier M, Sadeghi N, and Forghani R
- Subjects
- Cohort Studies, Humans, Operative Time, Postoperative Period, Quality Improvement, Retrospective Studies, Risk Factors, United States, Head and Neck Neoplasms surgery, Postoperative Complications epidemiology
- Abstract
Objective: Major postoperative adverse events (MPAEs) following head and neck surgery are not infrequent and lead to significant morbidity. The objective of this study was to ascertain which factors are most predictive of MPAEs in patients undergoing head and neck surgery., Methods: A cohort study was carried out based on data from patients registered in the National Surgical Quality Improvement Program (NSQIP) from 2006 to 2018. All patients undergoing non-ambulatory head and neck surgery based on Current Procedural Terminology codes were included. Perioperative factors were evaluated to predict MPAEs within 30-days of surgery. Age was classified as both a continuous and categorical variable. Retained factors were classified by attributable fraction and C-statistic. Multivariate regression and supervised machine learning models were used to quantify the contribution of age as a predictor of MPAEs., Results: A total of 43 701 operations were analyzed with 5106 (11.7%) MPAEs. The results of supervised machine learning indicated that prolonged surgeries, anemia, free tissue transfer, weight loss, wound classification, hypoalbuminemia, wound infection, tracheotomy (concurrent with index head and neck surgery), American Society of Anesthesia (ASA) class, and sex as most predictive of MPAEs. On multivariate regression, ASA class (21.3%), hypertension on medication (15.8%), prolonged operative time (15.3%), sex (13.1%), preoperative anemia (12.8%), and free tissue transfer (9%) had the largest attributable fractions associated with MPAEs. Age was independently associated with MPAEs with an attributable fraction ranging from 0.6% to 4.3% with poor predictive ability (C-statistic 0.60)., Conclusion: Surgical, comorbid, and frailty-related factors were most predictive of short-term MPAEs following head and neck surgery. Age alone contributed a small attributable fraction and poor prediction of MPAEs., Level of Evidence: 3.
- Published
- 2022
- Full Text
- View/download PDF
40. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study.
- Author
-
Albert JG, Lo C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Sultanem K, Shenouda G, Cury FL, and Henry M
- Subjects
- Anxiety psychology, Female, Humans, Longitudinal Studies, Prospective Studies, Body Image psychology, Head and Neck Neoplasms
- Abstract
(1) Background: Patients and survivors of head and neck cancer (HNC) are at a high risk of developing body image concerns. Despite the prevalence of body image concerns in patients with HNC, there is a lack of longitudinal research exploring the wide array of its associated determinants. The current longitudinal study examined the determinants and longitudinal course of body image dissatisfaction in patients with HNC. (2) Methods: Patients participated in Structured Clinical Interviews and self-administered questionnaires at four time-points: (T1) upon cancer diagnosis, (T2) at 3 months post-diagnosis, (T3) at 6 months post-diagnosis, and (T4) at 12 months post-diagnosis. They also underwent a disfigurement rating on an objective scale. (3) Results: Two hundred and twenty-four patients participated in our study. Fourteen percent to twenty-eight percent of patients reported at least moderate body image concerns across time points, with the lowest rates at baseline and the highest at 3 months (T1). It was found that patients more predisposed to developing higher levels of body image concerns presented physical markers (i.e., advanced cancer stage, lower physical functioning, higher disfigurement), psychosocial markers (i.e., higher depression, higher anxiety, and higher levels of coping with denial), and health disparities (i.e., younger age, female sex, French language, and marital status, with divorced and widowers most affected). (4) Conclusions: The findings of this study highlight the multifaceted nature of body image concerns in patients with HNC and its biopsychosocial determinants. Clinicians should pay specific attention to these biopsychosocial markers in their clinics to predict high levels of body image concerns and tailor communication/refer for support accordingly.
- Published
- 2022
- Full Text
- View/download PDF
41. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial.
- Author
-
Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, and Nichols AC
- Subjects
- Female, Humans, Male, Middle Aged, Quality of Life, Squamous Cell Carcinoma of Head and Neck therapy, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Head and Neck Neoplasms, Oropharyngeal Neoplasms radiotherapy, Oropharyngeal Neoplasms surgery, Papillomavirus Infections complications
- Abstract
Importance: The optimal approach for treatment deescalation in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCCs) is unknown., Objective: To assess a primary radiotherapy (RT) approach vs a primary transoral surgical (TOS) approach in treatment deescalation for HPV-related OPSCC., Design, Setting, and Participants: This international, multicenter, open-label parallel-group phase 2 randomized clinical trial was conducted at 9 tertiary academic cancer centers in Canada and Australia and enrolled patients with T1-T2N0-2 p16-positive OPSCC between February 13, 2018, and November 17, 2020. Patients had up to 3 years of follow-up., Interventions: Primary RT (consisting of 60 Gy of RT with concurrent weekly cisplatin in node-positive patients) vs TOS and neck dissection (ND) (with adjuvant reduced-dose RT depending on pathologic findings)., Main Outcomes and Measures: The primary end point was overall survival (OS) compared with a historical control. Secondary end points included progression-free survival (PFS), quality of life, and toxic effects., Results: Overall, 61 patients were randomized (30 [49.2%] in the RT arm and 31 [50.8%] in the TOS and ND arm; median [IQR] age, 61.9 [57.2-67.9] years; 8 women [13.6%] and 51 men [86.4%]; 31 [50.8%] never smoked). The trial began in February 2018, and accrual was halted in November 2020 because of excessive toxic effects in the TOS and ND arm. Median follow-up was 17 months (IQR, 15-20 months). For the OS end point, there were 3 death events, all in the TOS and ND arm, including the 2 treatment-related deaths (0.7 and 4.3 months after randomization, respectively) and 1 of myocardial infarction at 8.5 months. There were 4 events for the PFS end point, also all in the TOS and ND arm, which included the 3 mortality events and 1 local recurrence. Thus, the OS and PFS data remained immature. Grade 2 to 5 toxic effects occurred in 20 patients (67%) in the RT arm and 22 (71%) in the TOS and ND arm. Mean (SD) MD Anderson Dysphagia Inventory scores at 1 year were similar between arms (85.7 [15.6] and 84.7 [14.5], respectively)., Conclusions and Relevance: In this randomized clinical trial, TOS was associated with an unacceptable risk of grade 5 toxic effects, but patients in both trial arms achieved good swallowing outcomes at 1 year. Long-term follow-up is required to assess OS and PFS outcomes., Trial Registration: Clinicaltrials.gov Identifier: NCT03210103.
- Published
- 2022
- Full Text
- View/download PDF
42. Body Image Concerns in Patients With Head and Neck Cancer: A Longitudinal Study.
- Author
-
Henry M, Albert JG, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Lo C, and Rosberger Z
- Abstract
Objective: Head and neck cancer (HNC) treatments are known to significantly affect functionality and appearance, leading to an increased risk for body image disturbances. Yet, few longitudinal studies exist to examine body image in these patients. Based on a conceptual model, the current study aimed to determine, in patients newly diagnosed with HNC: (1) the prevalence, level, and course of body image concerns; (2) correlates of upon cancer diagnosis (pre-treatment) body image concerns; (3) predictors of immediate post-treatment body image concerns; and (4) association between body image concerns and levels of anxiety, depression, suicidal ideation, support (i.e., satisfaction with support from physician, social/family wellbeing, and unmet support needs), and alcohol and drug misuse., Methods: Two hundred and twenty-three (participation rate = 72%), newly diagnosed with a primary HNC were assessed using structured clinical interviews and psychometric measures at three, and 6 months after diagnosis. Primary outcome was 3-month, as it was most salient to body image disturbance. Multiple linear regression analyses were conducted on the potential body image predictors, based on the model., Results: Sixty-eight percent of patients with HNC ( n = 148 of 218) presented some level of body image concerns. Body image concerns at baseline (i.e., upon cancer diagnosis, pre-treatment) and post-treatment were significantly related and significantly increased from pre- to post-treatment. Immediately post-treatment (i.e., at 3 month follow-up), 89% ( n = 132 of 148) presented some level of body image concerns. Correlates of body image concerns in patients with HNC at baseline included: physical symptom burden, difficulties with communication and eating, coping with the cancer diagnosis using denial, suicidal ideation, and having had a past anxiety diagnosis. When controlling for sociodemographic and medical variables, body image concerns in patients with HNC in the immediate post-treatment were predicted by: baseline body image, physical symptom burden, and neuroticism., Conclusion: This longitudinal study helps identify patients more susceptible to experience body image disturbance following head and neck cancer. Clinicians ought to pay special attention to body image concerns upon cancer diagnosis, physical symptom burden, and neuroticism, and may want to target these factors in future preventive interventions., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Henry, Albert, Frenkiel, Hier, Zeitouni, Kost, Mlynarek, Black, MacDonald, Richardson, Mascarella, Morand, Chartier, Sadeghi, Lo and Rosberger.)
- Published
- 2022
- Full Text
- View/download PDF
43. Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial.
- Author
-
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Odell M, Parker C, Wehrli B, Kwan K, and Palma DA
- Subjects
- Humans, Quality of Life, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Deglutition Disorders etiology, Head and Neck Neoplasms, Oropharyngeal Neoplasms radiotherapy, Oropharyngeal Neoplasms surgery, Robotic Surgical Procedures adverse effects, Robotic Surgical Procedures methods
- Abstract
Purpose: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen rapidly, because of an epidemic of human papillomavirus infection. The optimal management of early-stage OPSCC with surgery or radiation continues to be a clinical controversy. Long-term randomized data comparing these paradigms are lacking., Methods: We randomly assigned patients with T1-T2, N0-2 (≤ 4 cm) OPSCC to radiotherapy (RT) (with chemotherapy if N1-2) versus transoral robotic surgery plus neck dissection (TORS + ND) (with or without adjuvant therapy). The primary end point was swallowing quality of life (QOL) at 1-year using the MD Anderson Dysphagia Inventory. Secondary end points included adverse events, other QOL outcomes, overall survival, and progression-free survival. All analyses were intention-to-treat. Herein, we present long-term outcomes from the trial., Results: Sixty-eight patients were randomly assigned (n = 34 per arm) between August 10, 2012, and June 9, 2017. Median follow-up was 45 months. Longitudinal MD Anderson Dysphagia Inventory analyses demonstrated statistical superiority of RT arm over time ( P = .049), although the differences beyond 1 year were of smaller magnitude than at the 1-year timepoint (year 2: 86.0 ± 13.5 in the RT arm v 84.8 ± 12.5 in the TORS + ND arm, P = .74; year 3: 88.9 ± 11.3 v 83.3 ± 13.9, P = .12). These differences did not meet the threshold to qualify as a clinically meaningful change at any timepoint. Certain differences in QOL concerns including more pain and dental concerns in the TORS + ND arm seen at 1 year resolved at 2 and 3 years; however, TORS patients started to use more nutritional supplements at 3 years ( P = .015). Dry mouth scores were higher in RT patients over time ( P = .041)., Conclusion: On longitudinal analysis, the swallowing QOL difference between primary RT and TORS + ND approaches persists but decreases over time. Patients with OPSCC should be informed about the pros and cons of both treatment options (ClinicalTrials.gov identifier: NCT01590355)., Competing Interests: Anthony C. NicholsResearch Funding: Novartis Canada Pharmaceuticals Inc (Inst) Eric BertheletResearch Funding: Eisai Eric WinquistConsulting or Advisory Role: Merck, Bayer, Eisai, Amgen, Roche, IpsenResearch Funding: Roche/Genentech (Inst), Merck (Inst), Pfizer (Inst), Eisai (Inst), Ayala Pharmaceuticals (Inst) David A. PalmaThis author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: London Health Sciences Centre (LHSC)Patents, Royalties, Other Intellectual Property: US patent: a method for analyzing a three-dimensional computed tomography image, US patent application no. 61/896349 (not licensed, no commercial or financial impact)No other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
44. Effect of Perioperative Patient Education via Animated Videos in Patients Undergoing Head and Neck Surgery: A Randomized Clinical Trial.
- Author
-
Turkdogan S, Roy CF, Chartier G, Payne R, Mlynarek A, Forest VI, and Hier M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Preoperative Period, Surveys and Questionnaires, Young Adult, Head and Neck Neoplasms surgery, Patient Education as Topic methods, Patient Satisfaction
- Abstract
Importance: Patient education and engagement is a pivotal component of surgical recovery. Ensuring proper patient education involves a thorough understanding of one's diagnosis and recovery plan, while reducing language and learning barriers to help patients make informed decisions and improve their hospital experience., Objective: To assess whether using an animated surgical guide will help patients who are undergoing head and neck surgery feel more satisfied with their surgery and recovery process., Design, Setting, and Participants: A randomized clinical trial was conducted between January and August 2020 at a single tertiary care academic center in Montreal, Canada. A consecutive sample of individuals who were undergoing any of the following surgical procedures was recruited: head and neck cancer resection with or without reconstruction, parotidectomy, thyroidectomy, parathyroidectomy, laryngectomy, or transoral robotic resection. The treating team was masked to group allocation, while study participants in the nonintervention group were unaware of the multimedia platform to avoid introducing bias in their survey responses., Interventions: Patients were randomly allocated to either the treatment arm, in which they obtained access to a multimedia patient education platform, or the control arm, in which they received traditional patient education methods via clinical visits., Main Outcomes and Measures: Primary analysis compared patient satisfaction scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire INFO 25, a validated questionnaire on the perceived quality of information received by patients with cancer (possible scores ranging from 20 to 80)., Results: A total of 100 patients (50 in each arm; 63 women [63%]; 6 African American [6%, 12 Hispanic/Latino [12%], 11 Middle Eastern [11%], and 78 White [78%] individuals) completed the preintervention and postintervention questionnaires. In those who received access to the patient education platform, there was an 11.3-point (Cohen d = 1.02; control group score, 61.1 of 80; treatment group score, 72.4 of 80) difference of greater postoperative satisfaction scores at 1 month. While both groups felt that they received an adequate amount of information concerning their disease process, patients in the treatment arm had significantly better satisfaction with information concerning their medical tests, treatments, and other services., Conclusions and Relevance: This randomized clinical trial of patients undergoing head and neck cancer treatment demonstrates that multimedia patient education platforms may enhance current traditional methods, providing complementary information on patients' treatment plans and recovery process, mental health, family life, and supplementary services. Further research is currently underway to confirm whether this platform will lead to decreased hospital stay, shorter complication rates, and long-term effects., Trial Registration: ClinicalTrials.gov Identifier: NCT04048538.
- Published
- 2022
- Full Text
- View/download PDF
45. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study.
- Author
-
Henry M, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, and Rosberger Z
- Subjects
- Humans, Longitudinal Studies, Papillomaviridae, Prospective Studies, Quality of Life, Alphapapillomavirus, Depressive Disorder, Major complications, Head and Neck Neoplasms complications, Head and Neck Neoplasms therapy, Papillomavirus Infections psychology
- Abstract
Objectives: Human papillomavirus (HPV) has prompted a need to further investigate how this new biomarker changes the head and neck cancer (HNC) psychosocial landscape. This study aimed to: (a) characterize the sociodemographic, psychological, and social profiles of patients with HPV-positive versus -negative squamous cell carcinoma of the head and neck; and (b) identify how HPV status contributes to anxiety and depression (primary outcome), quality of life (QoL), and sexuality needs., Methods: We conducted a prospective longitudinal study of 146 patients newly diagnosed with oral, oropharyngeal, nasopharyngeal, and hypopharyngeal cancer. Seventy-nine patients were HPV-positive and 67 HPV-negative. Patients completed self-administered psychometric measures upon HNC and 3-month follow-up, and Structured Clinical Interviews for DSM Diagnoses., Results: Patients with HPV-negative tumors generally presented with higher anxiety and depression and lower QoL immediately post-HNC diagnosis (<2 weeks) compared to HPV-positive cancers. A Major Depressive Disorder (MDD) immediately post-HNC diagnosis negatively affected patients' anxiety and depression and QoL levels upon diagnosis only when the cancer was HPV-positive. Immediately posttreatment, HPV status was not associated with outcomes. A previous history of suicidal ideation, and upon cancer diagnosis cigarette smoking, anxiety and depression, and feeling close to one's partner were instead explanatory., Conclusion: While patients with HPV-positive HNC generally present with initially lower psychological distress, their vulnerability immediately posttreatment indicates an equal need for support. Head and neck clinics may need to better address MDD, anxiety and depression, a prior history of suicidal ideation, health behavior change, and quality of relationships., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
46. Longitudinal study indicating antecedent psychosocial vulnerability as predictor of anxiety disorders post-treatment in people with head and neck cancer.
- Author
-
Henry M, Sargi E, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Chartier G, Sadeghi N, and Rosberger Z
- Subjects
- Anxiety psychology, Child, Humans, Longitudinal Studies, Prevalence, Anxiety Disorders diagnosis, Anxiety Disorders epidemiology, Head and Neck Neoplasms epidemiology, Head and Neck Neoplasms therapy
- Abstract
Objective: This study aimed to: (1) determine the contribution of pre-cancer psychosocial vulnerability as an independent predictor of anxiety disorder (AD) onset immediately post-treatment in patients diagnosed with a first occurrence of head and neck cancer (HNC), controlling for sociodemographics and medical variables; and (2) estimate prevalence of AD and identify trajectories from the moment of diagnosis to the immediate post-treatment (i.e., over a period of 3 months) in this population., Methods: Two-hundred twenty-four consecutive patients (participation rate = 72%) newly diagnosed with a primary HNC were assessed with a structured clinical interview for a mental disorder, validated psychometric measures, and medical chart reviews., Results: Twenty-five percent of patients presented a lifetime AD, 19.4% within 2 weeks of HNC diagnosis, and 16.6% immediately post-treatment; representing 26.7% of patients with AD at any timepoint from the moment of diagnosis to immediately post-treatment. Patients were more likely to present an AD immediately post-treatment when they: were diagnosed with advanced-stage cancer (OR = 3.40, p = 0.006), presented a upon cancer diagnosis AD (OR = 2.45, p = 0.008) and/or experienced childhood abuse (OR = 1.96, p = 0.03)., Conclusions: Several AD trajectories may arise when patients are diagnosed with primary HNC. Health professionals should address AD and screen for risk factors (i.e., advanced stage cancer, AD upon cancer diagnosis, history of childhood abuse) as early as possible to assure optimal mental health care in this vulnerable population., (© 2021 John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
47. Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy.
- Author
-
Hier J, Vachon O, Bernstein A, Ibrahim I, Mlynarek A, Hier M, Alaoui-Jamali MA, Maschietto M, and da Silva SD
- Subjects
- Genetic Predisposition to Disease, Humans, Molecular Targeted Therapy, Carcinoma, Squamous Cell genetics, DNA Methylation, Head and Neck Neoplasms genetics
- Abstract
In addition to chronic infection with human papilloma virus (HPV) and exposure to environmental carcinogens, genetic and epigenetic factors act as major risk factors for head and neck cancer (HNC) development and progression. Here, we conducted a systematic review in order to assess whether DNA hypermethylated genes are predictive of high risk of developing HNC and/or impact on survival and outcomes in non-HPV/non-tobacco/non-alcohol associated HNC. We identified 85 studies covering 32,187 subjects where the relationship between DNA methylation, risk factors and survival outcomes were addressed. Changes in DNA hypermethylation were identified for 120 genes. Interactome analysis revealed enrichment in complex regulatory pathways that coordinate cell cycle progression (CCNA1, SFN, ATM, GADD45A, CDK2NA, TP53, RB1 and RASSF1). However, not all these genes showed significant statistical association with alcohol consumption, tobacco and/or HPV infection in the multivariate analysis. Genes with the most robust HNC risk association included TIMP3, DCC, DAPK, CDH1, CCNA1, MGMT, P16, MINT31, CD44, RARβ. From these candidates, we further validated CD44 at translational level in an independent cohort of 100 patients with tongue cancer followed-up beyond 10 years. CD44 expression was associated with high-risk of tumor recurrence and metastasis (P = 0.01) in HPV-cases. In summary, genes regulated by methylation play a modulatory function in HNC susceptibility and it represent a critical therapeutic target to manage patients with advanced disease.
- Published
- 2021
- Full Text
- View/download PDF
48. Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation.
- Author
-
de Lima JM, Castellano LRC, Bonan PRF, de Medeiros ES, Hier M, Bijian K, Alaoui-Jamali MA, da Cruz Perez DE, and da Silva SD
- Subjects
- Animals, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic chemistry, Autophagy drug effects, Cell Line, Tumor, Cell Survival drug effects, Chitosan administration & dosage, Drug Liberation, Fluorouracil administration & dosage, Fluorouracil chemistry, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms pathology, Humans, Mice, Nanoparticles chemistry, Particle Size, Polyesters administration & dosage, Antimetabolites, Antineoplastic pharmacology, Chitosan chemistry, Head and Neck Neoplasms drug therapy, Nanoparticles administration & dosage, Polyesters chemistry
- Abstract
Head and neck squamous cell carcinoma (HNSCC), a prevalent cancer worldwide, has a high incidence of loco-regional dissemination, frequent recurrence, and lower 5-year survival rates. Current gold standard treatments for advanced HNSCC rely primarily on radiotherapy and chemotherapy but with limited efficacy and significant side effects. In this study, we characterized a novel 5-fluorouracil (5-FU) carrier composed of chitosan solution (CS) and polycaprolactone (PCL) microparticles (MPs) in HNSCC preclinical models. The designed MPs were evaluated for their size, morphology, drug entrapment efficiency (EE%) and in vitro drug release profile. The anti-cancer activity of 5-FU-loaded particles was assessed in HNSCC human cell lines (CAL27 and HSC3) and in a preclinical mouse model (AT84) utilizing cell proliferation and survival, cell motility, and autophagy endpoints. The results demonstrated a 38.57 % in 5-FU entrapment efficiency associated with reduced 5-FU in vitro release up to 96 h post-exposure. Furthermore, CS-decorated PCL MPs were able to promote a significant inhibition of cancer cell proliferation based on the metabolic and colony formation assays, in comparison to controls. In contrast, CS-decorated PCL MPs did not influence the pharmacological efficacy of 5-FU to inhibit in vitro cancer cell migration. Last, cell protein analysis revealed a significant increase of autophagy and cell death evaluated by LC3-II expression and PARP1 cleavage, respectively. In summary, these results support the potential utility of CS-decorated PCL MPs as an effective 5-FU-delivery carrier to improve HNSCC therapeutic management., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. Association of In-Ear Device Use With Communication Quality Among Individuals Wearing Personal Protective Equipment in a Simulated Operating Room.
- Author
-
Nguyen DL, Kay-Rivest E, Tewfik MA, Hier M, and Lehmann A
- Subjects
- Adult, Canada, Female, Health Personnel, Humans, Infection Control instrumentation, Male, Quality Improvement, SARS-CoV-2, Simulation Training, Speech Discrimination Tests methods, COVID-19 epidemiology, COVID-19 prevention & control, Communication, Hearing, Hearing Aids standards, N95 Respirators adverse effects, N95 Respirators standards, Operating Rooms organization & administration, Operating Rooms standards, Respiratory Protective Devices adverse effects
- Abstract
Importance: The COVID-19 pandemic has brought forth new challenges for health care workers, such as the daily use of personal protective equipment, including reusable facial respirators. Poor communication while wearing respirators may have fatal complications for patients, and no solution has been proposed to date., Objective: To examine whether use of an in-ear communication device is associated with improved communication while wearing different personal protective equipment (N95 mask, half-face elastomeric respirator, and powered air-purifying respirator [PAPR]) in the operating room., Design, Setting, and Participants: This quality improvement study was conducted in June 2020. Surgical residents from the Department of Otolaryngology-Head and Neck Surgery at McGill University in Montreal, Quebec, Canada, were recruited. All participants had normal hearing, were fluent in English, and had access to the operating rooms at the Royal Victoria Hospital., Exposures: All participants performed the speech intelligibility tasks with and without an in-ear communication device., Main Outcomes and Measures: Speech intelligibility was measured using a word recognition task (Modified Rhyme Test) and a sentence recognition task (AzBio Sentence Test). A percentage correct score (0% to 100%) was obtained for each speech intelligibility test. Listening effort was assessed using the NASA Task Load Index. An overall workload score, ranging from 0 points (low workload) to 100 points (high workload), was obtained., Results: A total of 12 participants were included (mean [SD] age, 31.2 [1.9] years; 8 women [66.7%]). AzBio Sentence Test results revealed that, while wearing the N95 mask, the mean (SD) speech intelligibility was 98.8% (1.8%) without the in-ear device vs 94.3% (7.4%) with the device. While wearing the half-face elastomeric respirator, the mean speech intelligibility was 58.5% (12.4%) without the in-ear device vs 90.8% (8.9%) with the device. While wearing the PAPR, the mean speech intelligibility was 84.6% (9.8%) without the in-ear device vs 94.5% (5.5%) with the device. Use of the in-ear device was associated with a significant improvement in speech intelligibility while wearing the half-face elastomeric respirator (32.3%; 95% CI, 23.8%-40.7%; P < .001) and the PAPR (9.9%; 95% CI, 1.4%-18.3%; P = .01). Furthermore, use of the device was associated with decreased listening effort. The NASA Task Load Index results reveal that, while wearing the N95 mask, the mean (SD) overall workload score was 12.6 (10.6) points without the in-ear device vs 17.6 (9.2) points with the device. While wearing the half-face elastomeric respirator, the mean overall workload score was 67.7 (21.6) points without the in-ear device vs 29.3 (14.4) points with the in-ear device. While wearing the PAPR, the mean overall workload score was 42.2 (18.2) points without the in-ear device vs 23.8 (12.8) points with the in-ear device. Use of the in-ear device was associated with a significant decrease in overall workload score while wearing the half-face elastomeric respirator (38.4; 95% CI, 23.5-53.3; P < .001) and the PAPR (18.4; 95% CI, 0.4-36.4; P = .04)., Conclusions and Relevance: This study found that among participants using facial respirators that impaired communication, a novel in-ear device was associated with improved communication and decreased listening effort. Such a device may be a feasible solution for protecting health care workers in the operating room while allowing them to communicate safely, especially during the COVID-19 pandemic.
- Published
- 2021
- Full Text
- View/download PDF
50. Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype.
- Author
-
da Silva SD, Marchi FA, Su J, Yang L, Valverde L, Hier J, Bijian K, Hier M, Mlynarek A, Kowalski LP, and Alaoui-Jamali MA
- Abstract
Invasive oral squamous cell carcinoma (OSCC) is often ulcerated and heavily infiltrated by pro-inflammatory cells. We conducted a genome-wide profiling of tissues from OSCC patients (early versus advanced stages) with 10 years follow-up. Co-amplification and co-overexpression of TWIST1 , a transcriptional activator of epithelial-mesenchymal-transition (EMT), and colony-stimulating factor-1 ( CSF1 ), a major chemotactic agent for tumor-associated macrophages (TAMs), were observed in metastatic OSCC cases. The overexpression of these markers strongly predicted poor patient survival (log-rank test, p = 0.0035 and p = 0.0219). Protein analysis confirmed the enhanced expression of TWIST1 and CSF1 in metastatic tissues. In preclinical models using OSCC cell lines, macrophages, and an in vivo matrigel plug assay, we demonstrated that TWIST1 gene overexpression induces the activation of CSF1 while TWIST1 gene silencing down-regulates CSF1 preventing OSCC invasion. Furthermore, excessive macrophage activation and polarization was observed in co-culture system involving OSCC cells overexpressing TWIST1 . In summary, this study provides insight into the cooperation between TWIST1 transcription factor and CSF1 to promote OSCC invasiveness and opens up the potential therapeutic utility of currently developed antibodies and small molecules targeting cancer-associated macrophages.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.